Company announcements · 17/10/20261 min read
Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia
Summary
Vivacta Bio, a biotechnology company spun out of Grit Bio, has received FDA orphan drug designation for its in vivo CAR-T therapy GT801 to treat autoimmune hemolytic anemia
Original source language: PR NewswireOpen original release →